샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536215

세계의 페닐케톤뇨증 치료 시장

Phenylketonuria Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 184 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 페닐케톤뇨증 치료 시장은 2030년까지 16억 달러에 달할 전망

2023년에 9억 7,500만 달러로 추정되는 세계의 페닐케톤뇨증 치료 시장은 분석 기간인 2023-2030년에 CAGR 7.0%로 성장하며, 2030년에는 16억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 Palynziq Drug는 CAGR 7.4%를 기록하며, 분석 기간 종료시에는 9억 1,820만 달러에 달할 것으로 예측됩니다. Kuvan Drug 부문의 성장률은 분석 기간 중 CAGR 6.6%로 추정됩니다.

미국 시장은 2억 6,560만 달러로 추정, 중국은 CAGR 11.2%로 성장 예측

미국의 페닐케톤뇨증 치료 시장은 2023년에 2억 6,560만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2023-2030년 CAGR 11.2%를 뒤쫓아 2030년까지 3억 4,390만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.0%와 6.9%로 예측됩니다. 유럽에서는 독일이 CAGR 4.4%로 성장할 것으로 예측됩니다.

세계의 페닐케톤뇨증 치료 시장 - 주요 동향과 촉진요인 정리

페닐케톤뇨증(PKU)은 아미노산 페닐알라닌 대사에 필요한 효소인 페닐알라닌수산화효소(PAH)의 결핍으로 인해 발생하는 희귀한 유전성 대사 질환으로, PAH가 결핍되거나 결핍되면 페닐알라닌이 혈액과 뇌에 축적되어 방치하면 심각한 인지 장애와 신경학적 문제를 일으킬 수 있습니다. PKU 관리의 기본은 고단백 식품을 배제하고 페닐알라닌이 함유되지 않은 특수 처방된 의료용 식품과 페닐알라닌이 함유되지 않은 아미노산 보충제를 섭취하는 엄격한 페닐알라닌 저함량 식이요법을 평생 동안 유지하는 것입니다. 신생아 스크리닝 프로그램을 통한 조기 진단은 치료되지 않은 PKU로 인한 심각한 결과를 예방하는 데 매우 중요하며, 적시에 식이요법을 시작하고 페닐알라닌 농도를 주의 깊게 모니터링할 수 있습니다.

최근 PKU 치료의 발전은 식이요법에만 국한되지 않고 환자의 예후와 삶의 질을 개선할 수 있는 새로운 치료 옵션을 제공합니다. 중요한 진전 중 하나는 보조 효소인 테트라하이드로비옵테린(BH4)의 합성 형태인 사프롭테린 이염산염과 같은 약리학적 치료법을 사용하여 경증에서 중등도 PKU 환자의 일부에서 PAH의 잔존 활성을 향상시킬 수 있습니다. 또한 효소 보충 요법인 페그바리아제는 식이 조절에도 불구하고 혈중 페닐알라닌 농도를 조절할 수 없는 성인 PKU 환자에게 승인되었습니다. 페그바리어제는 혈중 페닐알라닌을 분해해 효과를 발휘하며, 식이요법만으로는 페닐알라닌 농도를 낮게 유지하기 어려운 환자들에게 새로운 치료법이 될 수 있습니다. 유전자 치료 및 기타 혁신적인 치료법도 연구 중이며, PKU의 근본적인 유전적 원인을 해결함으로써 보다 영구적인 해결책을 제공하는 것을 목표로 하고 있습니다.

페닐케톤뇨증 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 의료진과 환자들 사이에서 PKU에 대한 인식과 이해도가 높아짐에 따라 보다 빠르고 정확한 진단이 가능해져 효과적인 치료에 대한 수요가 증가하고 있습니다. 기술 발전과 지속적인 연구로 새로운 약리 요법과 혁신적인 치료법 개발이 촉진되어 PKU 관리에 대한 선택의 폭이 넓어지고 있습니다. 또한 개인별 유전자 프로파일에 따라 치료를 맞춤화하는 맞춤형 의료의 부상도 보다 표적화되고 효과적인 치료법을 제공함으로써 시장 성장을 가속하고 있습니다. 또한 전 세계에서 신생아 선별검사 프로그램이 확대되면서 PKU의 검출률이 높아져 종합적인 치료 솔루션에 대한 필요성이 더욱 커지고 있습니다. 특수 의료용 식품 및 보충제의 접근성 향상과 희귀질환 치료에 대한 의료 정책 및 재정 지원과 더불어, 시장 환경은 양호한 시장 환경을 조성하고 있습니다. 이러한 추세에 따라 페닐케톤뇨증 치료 시장은 의학의 발전과 환자 예후 개선에 대한 관심 증가에 힘입어 큰 성장을 이룰 것으로 전망됩니다.

조사 대상 기업의 예(총 86건)

  • Ajinomoto Cambrooke, Inc.
  • American Gene Technologies Inc.
  • Arla Foods Ingredients Group P/S
  • BioMarin Pharmaceutical, Inc.
  • Codexis, Inc.
  • Metropolis Healthcare Ltd.
  • Nestle Health Science SA
  • Nutricia
  • PTC Therapeutics
  • SOM Biotech
  • Synlogic
  • Travere Therapeutics, Inc.
  • Ultragenyx Pharmaceutical, Inc.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.08.27

Global Phenylketonuria Treatment Market to Reach US$1.6 Billion by 2030

The global market for Phenylketonuria Treatment estimated at US$975.0 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Palynziq Drug, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$918.2 Million by the end of the analysis period. Growth in the Kuvan Drug segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$265.6 Million While China is Forecast to Grow at 11.2% CAGR

The Phenylketonuria Treatment market in the U.S. is estimated at US$265.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$343.9 Million by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Phenylketonuria Treatment Market - Key Trends and Drivers Summarized

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase (PAH), which is necessary for the metabolism of the amino acid phenylalanine. When PAH is deficient or absent, phenylalanine accumulates in the blood and brain, leading to severe cognitive impairments and neurological issues if left untreated. The cornerstone of PKU management has traditionally been a strict, lifelong diet low in phenylalanine, which involves the exclusion of high-protein foods and the inclusion of specially formulated medical foods and phenylalanine-free amino acid supplements. Early diagnosis through newborn screening programs has been critical in preventing the severe outcomes associated with untreated PKU, allowing for the timely initiation of dietary management and close monitoring of phenylalanine levels.

In recent years, advances in PKU treatment have expanded beyond dietary management, providing new therapeutic options that improve patient outcomes and quality of life. One significant development is the use of pharmacological treatments such as sapropterin dihydrochloride, a synthetic form of the cofactor tetrahydrobiopterin (BH4), which can enhance the residual activity of PAH in some patients with mild to moderate PKU. Additionally, pegvaliase, an enzyme substitution therapy, has been approved for adults with PKU who have uncontrolled blood phenylalanine levels despite dietary management. Pegvaliase works by breaking down phenylalanine in the bloodstream, offering a new avenue for those who struggle to maintain low phenylalanine levels through diet alone. Gene therapy and other innovative treatments are also under investigation, aiming to provide more permanent solutions by addressing the underlying genetic cause of PKU.

The growth in the phenylketonuria treatment market is driven by several factors. The increasing awareness and understanding of PKU among healthcare providers and patients have led to earlier and more accurate diagnoses, boosting the demand for effective treatments. Technological advancements and ongoing research have facilitated the development of new pharmacological therapies and innovative treatments, expanding the options available for PKU management. The rise of personalized medicine, which tailors treatments to individual genetic profiles, is also driving market growth by offering more targeted and effective therapies. Additionally, the expansion of newborn screening programs globally has increased the detection rates of PKU, further fueling the need for comprehensive treatment solutions. The growing availability of specialized medical foods and supplements, coupled with supportive healthcare policies and funding for rare disease treatments, are creating a favorable market environment. As these trends continue to evolve, the phenylketonuria treatment market is poised for significant growth, driven by advancements in medical science and a heightened focus on improving patient outcomes.

Select Competitors (Total 86 Featured) -

  • Ajinomoto Cambrooke, Inc.
  • American Gene Technologies Inc.
  • Arla Foods Ingredients Group P/S
  • BioMarin Pharmaceutical, Inc.
  • Codexis, Inc.
  • Metropolis Healthcare Ltd.
  • Nestle Health Science SA
  • Nutricia
  • PTC Therapeutics
  • SOM Biotech
  • Synlogic
  • Travere Therapeutics, Inc.
  • Ultragenyx Pharmaceutical, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Phenylketonuria Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness and Understanding of PKU Expands Addressable Market Opportunity
    • Advances in Pharmacological Treatments Strengthen Business Case for PKU Management
    • Rise of Personalized Medicine Propels Growth in Tailored Therapeutics
    • Expansion of Newborn Screening Programs Generates Demand for Early Intervention
    • Development of Enzyme Substitution Therapies Drives Adoption of New Treatments
    • Innovative Gene Therapy Research Throws the Spotlight on Potential Cure for PKU
    • Technological Advancements in Medical Foods and Supplements Accelerate Market Growth
    • Growing Availability of Specialized Medical Foods Spurs Market Demand
    • Rising Investment in Rare Disease Research Generates New Opportunities
    • Focus on Long-Term Health Outcomes Strengthens Case for Comprehensive Treatment Plans
    • Integration of Telehealth Services in PKU Management Propels Market Growth
    • Increasing Prevalence of PKU and Early Diagnoses Generate Demand for Advanced Therapies
    • Advances in Biotechnology Facilitate Development of Next-Generation PKU Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Phenylketonuria Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Phenylketonuria Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Palynziq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Palynziq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Palynziq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kuvan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kuvan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kuvan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Phenylketonuria Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Phenylketonuria Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Phenylketonuria Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Phenylketonuria Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Phenylketonuria Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Phenylketonuria Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Phenylketonuria Treatment by Drug Type - Palynziq, Kuvan and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Phenylketonuria Treatment by Drug Type - Percentage Breakdown of Value Sales for Palynziq, Kuvan and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제